MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585112 | Name: RCC-36 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rcc 36 is an active metabolite of temiverine that has inhibitory actions toward the atropine-resistant part of contractions, which may be related to the calcium antagonistic actions of these compounds.

Chemical Structure

RCC-36 HCl
RCC-36 HCl
CAS#129927-37-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 585112

Name: RCC-36 HCl

CAS#: 129927-37-3 (HCl)

Chemical Formula: C22H32ClNO3

Exact Mass: 393.2071

Molecular Weight: 393.95

Elemental Analysis: C, 67.07; H, 8.19; Cl, 9.00; N, 3.56; O, 12.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
129927-37-3 (free base) 129927-37-3 (HCl)
Synonym
RCC-36; RCC 36; RCC36; RCC-36 HCl; RCC-36 hydrochloride
IUPAC/Chemical Name
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(ethylamino)-1,1-dimethyl-2-butynyl ester, hydrochloride
InChi Key
AEPBOUHKRSABGU-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H31NO3.ClH/c1-4-23-17-11-16-21(2,3)26-20(24)22(25,18-12-7-5-8-13-18)19-14-9-6-10-15-19;/h5,7-8,12-13,19,23,25H,4,6,9-10,14-15,17H2,1-3H3;1H
SMILES Code
O=C(OC(C)(C)C#CCNCC)C(O)(C1CCCCC1)C2=CC=CC=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 393.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer. 2016 Feb 8;16:67. doi: 10.1186/s12885-016-2097-4. PubMed PMID: 26857818; PubMed Central PMCID: PMC4746884. 2: Yang JF, Zhang XY, Qi F. [Expression of S100 protein in renal cell carcinoma and its relation with P53]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004 Jun;29(3):301-4. Chinese. PubMed PMID: 16136965. 3: Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol. 2001 Sep-Oct;22(5):282-5. PubMed PMID: 11553857. 4: Braga E, Pugacheva E, Bazov I, Ermilova V, Kazubskaya T, Mazurenko N, Kisseljov F, Liu J, Garkavtseva R, Zabarovsky E, Kisselev L. Comparative allelotyping of the short arm of human chromosome 3 in epithelial tumors of four different types. FEBS Lett. 1999 Jul 9;454(3):215-9. PubMed PMID: 10431810. 5: Kikukawa H, Yoshida M, Wada Y, Nishi K, Ueda S. Pharmacologic actions of temiverine (p-INN) and its active metabolite, RCC-36, on isolated human urinary bladder muscle. Int J Urol. 1998 May;5(3):268-75. PubMed PMID: 9624560. 6: Natsukawa T, Matsuzaki T, Hayashi S, Ukai Y, Yoshikuni Y, Kimura K. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. Gen Pharmacol. 1998 Jan;30(1):137-42. PubMed PMID: 9457495. 7: Hamada K, Sasaki Y, Taniguchi N, Fukui H, Miyatsuka Y, Kimura Y, Ukai Y, Yoshikuni Y, Kimura K. Anticholinergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions. Gen Pharmacol. 1997 Nov;29(5):771-8. PubMed PMID: 9347324. 8: Sasaki Y, Hamada K, Yamazaki C, Seto T, Kimura Y, Ukai Y, Yoshikuni Y, Kimura K. Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. Int J Urol. 1997 Jul;4(4):401-6. PubMed PMID: 9256331. 9: Hayashi S, Natsukawa T, Ukai Y, Yoshikuni Y, Kimura K. Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):659-66. PubMed PMID: 9151307. 10: Hayashi S, Natsukawa T, Suma C, Ukai Y, Yoshikuni Y, Kimura K. Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline. Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):651-8. PubMed PMID: 9151306. 11: Hatch RC, Regan KS, Ishibashi S, Nakazawa M, Iwakura K, Sumi N. Two-year dietary carcinogenicity study of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. J Toxicol Sci. 1997 Apr;22 Suppl 1:289-306. PubMed PMID: 9170616. 12: Hatch RC, Regan KS, Ishibashi S, Nakazawa M, Iwakura K, Sumi N. Seventy-eight-week dietary carcinogenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. J Toxicol Sci. 1997 Apr;22 Suppl 1:275-87. PubMed PMID: 9170615. 13: Tamura H, Yamashita Y, Kitayama E, Iwakura K, Watanabe M, Sumi N. [Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence]. J Toxicol Sci. 1997 Apr;22 Suppl 1:263-74. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170614. 14: Nakazawa M, Kitayama E, Adachi T, Yoshida M, Ishibashi S, Yoshikawa K, Kajihara T, Iwakura K, Sumi N. [Toxicokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice and rats during 13-week dietary administration]. J Toxicol Sci. 1997 Apr;22 Suppl 1:177-85. Japanese. Erratum in: J Toxicol Sci 1998 Oct;23 Suppl 4:664-9. PubMed PMID: 9170607. 15: Yoshida M, Kawaminami A, Tawaratani T, Ishibashi S, Nakazawa M, Kitayama E, Oka T, Adachi T, Iwakura K, Sumi N. [A 12-month oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 2-month recovery test]. J Toxicol Sci. 1997 Apr;22 Suppl 1:147-75. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170606. 16: Furukawa S, Kouyama H, Kikumori M, Taniguchi Y, Nishimori T, Ishibashi S, Iwakura K, Sumi N. [Oral single-dose and 13-week repeat-dose toxicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in rats]. J Toxicol Sci. 1997 Apr;22 Suppl 1:93-124. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:435. PubMed PMID: 9170604. 17: Okasaki K, Baba S, Ikeda H, Chihaya Y, Satake S, Nagata R, Ishibashi S, Iwakura K, Sumi N. [A 26-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats followed by a 9-week recovery test]. J Toxicol Sci. 1997 Apr;22 Suppl 1:59-92. Japanese. Erratum in: J Toxicol Sci 1997 Nov;22 Suppl 2:433. PubMed PMID: 9170603. 18: Nishimura N, Kobayashi J, Moro M, Katsumata T, Nishiguchi Y, Iwakura K, Sumi N. [Intraperitoneal single-dose toxicity studies of active metabolite, optical isomers, hydrolysis products and bi-product of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in mice]. J Toxicol Sci. 1997 Apr;22 Suppl 1:15-25. Japanese. PubMed PMID: 9170601. 19: Kimura Y, Hamada K, Fukui H, Ogasawara T, Ukai Y, Yoshikuni Y, Kimura K. Effect of the anticholinergic drug with calcium antagonistic activity, (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on lower urinary tract function in rhesus monkeys. Arzneimittelforschung. 1997 Feb;47(2):189-94. PubMed PMID: 9079239. 20: Kimura Y, Fukui H, Hamada K, Ogasawara T, Yamazaki C, Ukai Y, Yoshikuni Y, Kimura K. Effect of the anticholinergic drug with calcium antagonistic activity, (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on lower urinary tract function in decerebrated dogs. Arzneimittelforschung. 1997 Feb;47(2):182-9. Erratum in: Arzneimittelforschung 1997 Apr;47(4):420. PubMed PMID: 9079238.

View History

BAY-985

BAY-985

Featured